Skip to main content
Premium Trial:

Request an Annual Quote

Kyowa CDx Tests Approved by Regulators in Japan

NEW YORK (GenomeWeb News) – Japanese reagent and medical device firm Kyowa Medex today announced regulators in Japan have approved two companion diagnostics for a drug targeting adult T-cell leukemia-lymphoma (ATL).

The Ministry of Health, Labour, and Welfare approved Kyowa's Poteligeo Test IHC and Poteligeo Test FCM for Kyowa Hakko Kirin's Poteligeo (mogamulizumab) injection, a therapeutic antibody that was also approved by MHLW today.

Kyowa Medex is a wholly owned subsidiary of Kyowa Hakko Kirin.

Poteligeo binds to CCR4, which is expressed on the surface of ATL cells. ATL cells are killed by antibody-dependent cell-mediated cytotoxicity activity. The two companion diagnostic tests approved today detect for the presence of CCR4 expressed by ATL cells before treatment with Poteligeo. As a result, physicians can identify patients who would most benefit from the drug, Kyowa said.

Poteligeo Test IHC is immunhistochemistry-based and is for use on tissue samples, such as lymph nodes. Poteligeo Test FCM uses flow cytometry to analyze blood samples from patients.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.